LiDCO : Master distribution agreement & other distributors

LIDCO GROUP PLC

('LiDCO' or the 'Company' or 'the Group')

& new distributors for India and Malaysia

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has signed a master distribution agreement for LiDCO products with LOK Corporation covering a number of territories across sub-Saharan Africa. This announcement follows on from the agreement signed with LOK Corporation for Canada which was announced in the Company's Trading Update issued on 8 February 2016.

This new 3 year agreement covers a number of countries in Southern Africa, namely Botswana,Kenya, Mozambique, Namibia, Nigeria, Lesotho, South Africa, Swaziland, Tanzania and Zimbabwe. LOK Corporation will actively promote the LiDCO product range and take responsibility for distributor management in those countries, as well as undertake the co-ordination of regulatory and registration requirements needed in each territory.

This agreement is a further extension of the Company's new approach to global marketing and distribution management, and aligns with the master distribution agreement signed with Fieldman Medical in November 2015, which has seen LiDCO products marketed across numerous territories in South East Asia & Australia.

In addition, the Company has sought to engage distributors in key markets such as India and Malaysia. The Company has recently appointed two partners in these regions, both with a strong knowledge of their respective local markets, and these distributors have now taken delivery of LiDCO products and are actively marketing them.

Commenting Matt Sassone, Chief Executive Officer, said:

'As I communicated to investors in our Half Yearly Report, we expect that geographical expansion will remain the biggest driver of future growth for LiDCO and accordingly we are keenly expanding our distribution network globally. We are delighted to extend our relationship with LOK to include Africa as well as Canada, and we recognise that India and Asia present great opportunities for us as the benefits of hemodynamic monitoring are being adopted globally more and more.'

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity:a hemodynamic monitor that combines the full suite of LiDCO technology (LiDCOplus,LiDCOrapidand LiDCOview) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapidprovides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapidallows the LiDCOrapidmonitor to co-display Covidien's level of consciousness parameter ('BIS)* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplusand LiDCOrapidhemodynamic data.

*BIS and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

**CNAP is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USAand through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.

LIDCO Group plc issued this content on 24 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 24 March 2016 07:10:58 UTC

Original Document: http://www.digitallook.com/ir/security.cgi?csi=31227&action=news&story_id=24166020&rns=1